6 Maggio 2019

FDA Approves Adjuvant T-DM1 in HER2+ Early Breast Cancer

May 3, 2019 – The FDA has approved ado-trastuzumab emtansine (T-DM1) for use as an adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant trastuzumab and chemotherapy. The approval is based on findings from the phase III KATHERINE study, in which T-DM1 reduced the risk of invasive disease recurrence or death by 50% compared with trastuzumab in this setting. The 3-year invasive disease- … (leggi tutto)